Introduction

Thyroid disorders are the second most common endocrine disorders found in pregnancy. Imbalances in thyroid homeostasis are expressed as hypothyroidism or hyperthyroidism. Autoimmune thyroid disease is a common cause of both hyperthyroidism and hypothyroidism in pregnant women. The prevalence rates of thyroid disorders in 147 Tunisian pregnant women were 6.5%, 3.2%, and 1.3% for positive TPO-Ab, hypothyroidism and hyperthyroidism respectively. The precise prevalence of thyroid autoimmunity in pregnant Nigerian women is not known. In view of the adverse pregnancy outcomes associated with thyroid autoimmunity this study set out to determine the relationship between pregnancy and thyroid autoimmunity in Nigerian women.
the prevalence of autoimmune thyroid disorders (AITD) in pregnant Nigerian women and also the relationship between gestational age and thyroid autoimmunity in Nigerian women.

**Subjects and Methods**

This analytical cross-sectional study was carried out at the Lagos University Teaching Hospital (LUTH), a Tertiary Hospital located in the South Western Region of Nigeria. This hospital is one of the main referral medical institutions in Lagos State. The hospital comprises 13 clinical departments, including: Medicine, Surgery, Paediatrics, Obstetrics and Gynaecology, Radiodiagnosis among others.[11] The Obstetrics and Gynaecology Department of LUTH run clinics in the mornings for pregnant and postpartum women four times a week. The number of pregnant women attending the prenatal clinics is about 280 every week. Ethical approval was obtained from the Ethics Committee of LUTH.

The study participants were selected from pregnant women who attended the hospital for their antenatal care during the period of study from April to September 2012. The women were selected from a list obtained at each visit from the medical records officer. To be eligible singleton pregnancy must have been confirmed with an obstetric ultrasound scan. The controls were nonpregnant women selected from among the female members of the staff of LUTH with a similar age to the pregnant women in a 1:2 ratio. Pregnancy was excluded if the urine β human chorionic gonadotropin pregnancy test was negative. Women with a personal or family history of thyroid dysfunction or diabetes mellitus were excluded. All participants gave written informed consent.

Using a 95% confidence interval, a margin of error of 5% and a prevalence of autoimmune thyroid disease of 6.5%, a minimum sample size of 94 was obtained.[10]

All participants had their demographic information obtained using the questionnaires administered by trained research assistants. Information obtained from each participant included age at last birthday, marital status, and the highest level of education. Physical examination was carried out. Serum thyroid stimulating hormone (TSH), free thyroxine (fT4), and TPO-Ab were quantitatively determined using enzyme-linked immuno-assays in 108 pregnant and 52 nonpregnant women. Being euthyroid was defined as TSH of 0.17–4.81 µIU/ml and fT4 within 9.5–20.6 pmol/L. Levels of TPO-Ab above 14.4 IU/ml (the 97.5th percentile of the values obtained from the controls) were deemed elevated and indicative of autoimmune thyroid disease.[12] Data analysis was performed using Statistical Package for the Social Science version 17th edition. Analysis of variance was used in comparison of means, Chi-square test used in analyzing proportions, Spearman correlation was used to determine the relationship between TPO-Ab levels with gestational age while P ≤ 0.05 was considered to be significant.[13]

**Results**

One hundred and eight pregnant and 52 nonpregnant women were studied [Table 1]. The mean age of the pregnant women of 30.4 ± 6.0 years was similar to that of the nonpregnant women of 30.5 ± 6.2 years (P = 0.7). The proportions of study participants in each age category are also shown in Table 1. The mean gestational age of all pregnant women was 20.6 ± 9.6 weeks ranging from 7 to 39 weeks with a median age of 19 weeks. Forty-one (38%) were primigravida, while 67 (62%) were multigravida.

Table 1 shows the proportions of study participants in each age category and in each pregnancy group.

The mean levels of TSH, fT4, and TPO-Ab in both the pregnant and control subjects are shown in Table 2. Thyroid disorders were observed in 32 (29.6%) pregnant women. Elevated TPO-Ab was observed in 27 (25%) women, hypothyroidism in 3 (2.8%) women while subclinical hyperthyroidism was observed in 2 (1.8%) women. Out of the 27 women with elevated TPO-Ab, 25 (92.6%) were euthyroid. One out of the 3 women (33.3%) with...
hypothyroidism had elevated TPO-Ab while one out of the 2 women (50%) with hyperthyroidism had elevated TPO-Ab.

The mean TPO-Ab levels in the three groups were 12.11 ± 5.49 IU/ml, 12.21 ± 5.37 IU/ml and 10.25 ± 4.06 IU/ml in the first, second, and third groups respectively.

The prevalence of autoimmune thyroid dysfunction in pregnancy was 25% while it was 1.9% in the nonpregnant women \( P < 0.001 \). Out of the 36 pregnant women who had TPO-Ab testing conducted in the first group, 12 (33.3%) had elevated TPO-Ab levels. Out of these 12 women, 10 of them were euthyroid. Ten (25.6%) of the 39 pregnant women in the second group had elevated TPO-Ab levels while 5 (15.2%) out of the 33 pregnant women in the third group had elevated TPO-Ab levels \( P = 0.21 \) [Figure 1].

Correlation analysis performed showed there was an insignificant negative correlation between TPO-Ab levels and gestational age (Spearman’s correlation coefficient \( r = -0.16; \ P = 0.09 \)). With increasing gestational age, TPO-Ab levels decline.

**Discussion**

In this study, the most common form of thyroid disorder was elevated levels of TPO-Ab. This finding was similar to what was reported in the Tunisian study where elevated levels of TPO-Ab was also the commonest thyroid disorder. Hypothyroidism was present in 2.8% of the women and is similar to that reported in American and European pregnant women.[14] During pregnancy, there is increased thyroid hormone production and increased foetal iodine requirements. Consequently, dietary iodine requirements are higher in pregnancy than they are for nonpregnant adults. Women with adequate iodine intake before and during pregnancy have adequate intra-thyroidal iodine stores and remain euthyroid. For those with inadequate iodine intake before and during pregnancy maternal hypothyroidism occurs as increased demand of pregnancy will outstrip supply.[2]

Hypothyroidism was associated with elevated levels of TPO-Ab in 33.3% of women. This shows that autoimmunity is a common cause of hypothyroidism in pregnant women.[10] The presence of hypothyroidism amongst the other women without autoimmunity could be as a result of iodine deficiency. Though Lagos is considered iodine sufficient area, studies carried out in some iodine sufficient areas have reported iodine deficits in women.[10] Subclinical hyperthyroidism was present in 1.9% of the pregnant women. Both women were in the first group. The cause of subclinical hyperthyroidism was related to autoimmunity in 50% while another cause could be transient gestational thyrotoxicosis since there was absence of elevated levels of TPO-Ab and this usually occurs in the first 13 weeks of pregnancy.

Autoimmune thyroid dysfunction was prevalent in 25% of pregnant women while it was 1.9% in the nonpregnant women. The value found in this study was higher than what was reported in pregnant women from Tunisia, Belgium, Japan, Turkey, Spain and the United States where 6.5%, 6.3%, 10%, 12%, 14.8%, and 20% respectively were positive for TPO-Ab.[10,15–18] The reason for this high prevalence of autoimmune thyroid dysfunction 25% in these pregnant women is difficult to explain. It could be due to variations in the assays used to measure TPO-Ab in the different studies. At present, there is no international standardization of the assays. It was also observed that in all the studies, different cut-off values were used to define autoimmune thyroid dysfunction. In this study, cut off values of 14.4 IU/ml was used.

The prevalence of elevated TPO-Ab decreased with gestational age from 33.3% in the first group to 25.6% and 15.2% in the women in second and third groups respectively. The same trend was observed in the study in Tunisian women where there was a decrease of positive TPO-Ab (from 7.7% to 4.7%) through gestation.[10] Previous studies have demonstrated that thyroid antibodies TPO-Ab, TgAb, and TRAb all decline during pregnancy and increase in the postpartum period.[19–22] During pregnancy, thyroid antibody titers decline due to the immuno-suppressive effect of pregnancy and subsequently

![Figure 1: Relationship between Autoimmune Thyroid Disorder and Gestational Age](http://www.ijem.in)
titers increase in the postpartum period.[10,23‑27] Important adaptations of the maternal immune system occur during pregnancy. Placental trophoblast cells secrete a variety of cytokines, several immunomodulatory molecules and hormones. These secretions induce a physiological immunosuppression response, which allows the maternal immune system to tolerate the foetus. During pregnancy B-cell production and activity are down regulated, leading to a reduction in antibody production.[28] There is also an increase in plasma levels of estrogen, progesterone, and corticosteroids. Corticosteroids induce immune cell apoptosis and immunosuppression while estrogen produces negative regulation of B cell activity.[28] The immunomodulatory molecules like Fas-Ligand induces apoptosis on fetal antigen-reactive maternal lymphocytes while human leukocyte antigen-G inhibits both natural killer NK cell function and maturation of dendritic cells. All these changes result in a general improvement in autoimmune intolerance during gestation.[28]

This study found that 25 out of 27 (92.6%) women with elevated TPO-Ab were euthyroid. Pregnant women with asymptomatic AITD carry a significant risk of developing hypo-thyroidism.[29] It has been shown that 33–50% of women who are positive for TPO or Tg antibody in the first 13 weeks of pregnancy will develop postpartum thyroiditis.[30] Screening for antibodies in the early months of pregnancy is justified to reduce adverse pregnancy outcomes like the increased risk of spontaneous miscarriage; progressive hypothryoidism during gestation; postpartum thyroiditis after pregnancy; and the long-term risk of developing definitive hypothyroidism later on in life. It is important that all pregnant women with AITD should be monitored closely and jointly by obstetricians and endocrinologists.[31]

**Conclusion**

Thyroid autoimmunity expressed by the presence of TPO-Ab is high among pregnant Nigerian women, and the degree of autoimmunity decreases with advancing gestation. Screening for thyroid autoimmunity is best performed in the first 13 weeks of pregnancy. It is important that all pregnant women with AITD be monitored closely and jointly by obstetricians and endocrinologists to reduce adverse maternal and fetal outcomes.

**References**

1. Nguyen PH. Autoimmune thyroid disease and pregnancy. In: Ronald L, Francisco T, Carle VS, Fedrick BG, Lee PS, editors. eMedicine World Medical Library, 2004. p. 1-20. Available from: http://www.F:autoimmune.in.preg.htm. [Last accessed on 2013 Jul 31].

2. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457.

3. Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:63-8.

4. Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2000;7:127-30.

5. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Thyroid antibody positivity in the first trimester of pregnancy is associated with negative pregnancy outcomes. J Clin Endocrinol Metab 2011;96:E920-4.

6. Stagnaro-Green A. Screening pregnant women for overt thyroid disease. JAMA 2015;313:565-6.

7. Negro R, Formoso G, Mangieri T, Pizzarroso A, Dazzi D, Hassan H. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006;91:2587-91.

8. Poppe K, Velleniers B, Ginoer D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab 2008;4:394-405.

9. Pop VP, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 1999;50:149-55.

10. Feki M, Omar S, Menif O, Tanfous NB, Slimane H, Zouari F, et al. Thyroid disorders in pregnancy: frequency and association with selected diseases and obstetrical complications in Tunisian women. Clin Biochem 2008;41:927-31.

11. Available from: http://www.luthnigeria.org. [Last accessed on 2012 Sep 18].

12. Moradi S, Gohari MR, Aghili R, Kashanian M, Ebrahimi H. Thyroid function in pregnant women: iodine deficiency after iodine enrichment program. Gynecol Endocrinol 2013;29:596-9.

13. Oluwadiya K. Getting to Know SPSS: A Step by Step Guide. 2nd ed. Oluwadiya Keinde; 2009. [Last accessed on 2013 Jul 31].

14. Mandel SJ. Hypothyroidism and chronic autoimmune thyroiditis in the pregnant state: maternal aspects. Best Pract Res Clin Endocrinol Metab 2004;18:213-24.

15. Mostman JH. Hyperthyroidism in pregnancy. Best Pract Res Clin Endocrinol Metab 2004;18:267-88.

16. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol 2005;105:239-45.

17. Bagis T, Gokcel A, Saygili ES. Autoimmune thyroid disease in pregnancy and the postpartum period: Relationship to spontaneous abortion. Thyroid 2001;11:1049-53.

18. Lejeune B, Grun JP, de Nayer P, Servais G, Glinoer D. Antithyroid antibodies underlying thyroid abnormalities and miscarriage or pregnancy induced hypertension. Br J Obstet Gynaecol 1993;100:669-72.

19. Smyth PP. Variation in iodine handling during normal pregnancy. Thyroid 1999;9:637-42.

20. Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, Miyai K. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves’ disease. J Clin Endocrinol Metab 1987;65:324-30.

21. Parker RH, Beierwaltes WH. Thyroid antibodies during pregnancy and in the newborn. J Clin Endocrinol Metab 1961;21:792-8.

22. Amino N, Mori H, Iwutani Y, Tanizawa O, Kawashima M, Tsuge I,
et al. High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N Engl J Med 1982;306:849-52.
23. Iijima T, Tada H, Hidaka Y, Mitsuda N, Murata Y, Amino N. Effects of autoantibodies on the course of pregnancy and fetal growth. Obstet Gynecol 1997;90:364-9.
24. Smallridge RC. Postpartum thyroid disease: A model of immunologic dysfunction. Clin Appl Immunol Rev 2000;1:89-103.
25. Pearce EN, Oken E, Gillman MW, Lee SL, Magnani B, Platek D, et al. Association of first-trimester thyroid function test values with thyroperoxidase antibody status, smoking, and multivitamin use. Endocr Pract 2008;14:33-9.
26. Weetman AP. The immunology of pregnancy. Thyroid 1999;9:643-6.
27. Davies TF. The thyroid immunology of the postpartum period. Thyroid 1999;9:675-84.
28. Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt) 2009;18:1847-56.
29. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997;18:404-33.
30. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011;21:1081-125.
31. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55-68.